ARGX-111, the final optimized antibody deriving from this series, is characterized by improved tissue penetration and enhanced ADCC, which result in increased anti-tumor and anti-metastatic activity in mouse xenograft models of both HGF-dependent and HGF-independent tumors (TAT—Targeted anticancer Therapies—2014 abstract [105]). This evidence concerns the gene HGF and neoplasm.